Company Filing History:
Years Active: 2023-2025
Title: Daigo Inoyama: Innovator in Pharmaceutical Compounds
Introduction
Daigo Inoyama is a notable inventor based in Ridgewood, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with KDM5 inhibitory activity. His work is aimed at addressing serious health conditions such as cancer, Huntington's disease, and Alzheimer's disease.
Latest Patents
Inoyama holds 2 patents related to his innovative compounds. His latest patents include a compound having KDM5 inhibitory activity and its pharmaceutical use. These compounds are disclosed in a specific formula, where all symbols have defined meanings as described in the specification. The compounds or their salts are recognized for their potential as prophylactic and therapeutic agents for various diseases, including cancer and neurodegenerative disorders.
Career Highlights
Inoyama is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key player in the pharmaceutical industry, contributing to the creation of effective treatments for debilitating diseases.
Collaborations
Inoyama collaborates with talented coworkers such as Akito Kakuuchi and Shuhei Umemura. Their combined expertise enhances the innovative environment at Ono Pharmaceutical Co., Ltd., fostering the development of groundbreaking pharmaceutical solutions.
Conclusion
Daigo Inoyama's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes through research and development. His work in creating compounds with KDM5 inhibitory activity is paving the way for new therapeutic options in the fight against serious diseases.